OVID Stock Price, Chart, Stats & News
Ovid Therapeutics Inc (OVID) does not currently pay a dividend.
OVID chart
Fundamentals
Gross margin | 95.86% |
Operating margin | -585.20% |
Pretax margin | -240.11% |
Net margin | -240.11% |
Effective tax rate | – |
ROA | -11.54% |
ROE | -23.98% |
D/E | 0.10x |
Interest coverage ratio | – |
OVID valuation
P/E | – |
P/S | 48.63x |
P/B | 1.44x |
P/CF | -4.90x |
P/FCF | -9.20x |
P/OCF | -4.90x |
PEG | -0.22x |
EV multiple | -8.43x |
About
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins.
Similar securities
Based on sector and market capitalization
